409 related articles for article (PubMed ID: 15867774)
1. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
2. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
Liu Z; Klominek J
Neoplasia; 2004; 6(6):705-12. PubMed ID: 15720796
[TBL] [Abstract][Full Text] [Related]
4. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases.
Harvey P; Clark IM; Jaurand MC; Warn RM; Edwards DR
Br J Cancer; 2000 Nov; 83(9):1147-53. PubMed ID: 11027427
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
[TBL] [Abstract][Full Text] [Related]
8. Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.
Zhang YG; Du Q; Fang WG; Jin ML; Tian XX
Int J Oncol; 2008 Sep; 33(3):595-602. PubMed ID: 18695891
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
[TBL] [Abstract][Full Text] [Related]
11. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
12. Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion.
Takenaga K
Invasion Metastasis; 1996; 16(2):97-106. PubMed ID: 9030244
[TBL] [Abstract][Full Text] [Related]
13. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal V; Lind MJ; Cawkwell L
Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
[TBL] [Abstract][Full Text] [Related]
14. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
Nasreen N; Mohammed KA; Antony VB
Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
[TBL] [Abstract][Full Text] [Related]
17. Translational therapies for malignant pleural mesothelioma.
Belli C; Anand S; Tassi G; Fennell D; Mutti L
Expert Rev Respir Med; 2010 Apr; 4(2):249-60. PubMed ID: 20406091
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
20. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
